Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
The depressant synergies between these medications can lead to dangerous complications, including severe hypoxia and respiratory failure
PLoS Pathog
NADPH oxidase regulates Paraquat and maneb-induced dopaminergic neurodegeneration through ferroptosis
An RCT in patients receiving cisplatin chemotherapy found that NAC (1,200 mg/day) significantly reduced nephrotoxicity and ototoxicity without reducing antitumor efficacy (Riga et al., Am J Clin Oncol, 2013) [77]
US$ 25.03
US$ 23.41
US$ 26.59
US$ 24.99
US$ 27.94
